NO965621L - Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 - Google Patents

Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Info

Publication number
NO965621L
NO965621L NO965621A NO965621A NO965621L NO 965621 L NO965621 L NO 965621L NO 965621 A NO965621 A NO 965621A NO 965621 A NO965621 A NO 965621A NO 965621 L NO965621 L NO 965621L
Authority
NO
Norway
Prior art keywords
mutant proteins
pct
antagonists
human interleukin
partial agonists
Prior art date
Application number
NO965621A
Other languages
English (en)
Other versions
NO965621D0 (no
Inventor
Hanno Wild
Rudolf Hanko
Michael Doerschug
Hans-Dietrich Hoerlein
Juergen Beunink
Heiner Apeler
Hermann Wehlmann
Walter Sebald
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO965621D0 publication Critical patent/NO965621D0/no
Publication of NO965621L publication Critical patent/NO965621L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det blir beskrevet hIL-4-mutantproteiner, fremgangsmåter for fremstilling av dem og deres anvendelse som medikamenter, spesielt for behandling av overskudds, feilregu-lerte immunoreaksjoner og autoimmune sykdommer.
NO965621A 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4 NO965621L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4423131A DE4423131A1 (de) 1994-07-01 1994-07-01 Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
PCT/EP1995/002358 WO1996001274A1 (de) 1994-07-01 1995-06-19 NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4

Publications (2)

Publication Number Publication Date
NO965621D0 NO965621D0 (no) 1996-12-30
NO965621L true NO965621L (no) 1996-12-30

Family

ID=6522032

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965621A NO965621L (no) 1994-07-01 1996-12-30 Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4

Country Status (18)

Country Link
US (1) US6130318A (no)
EP (1) EP0769020B1 (no)
JP (3) JPH10502360A (no)
KR (1) KR100393508B1 (no)
AT (1) ATE190068T1 (no)
AU (1) AU705745B2 (no)
CA (1) CA2193993C (no)
CZ (1) CZ292703B6 (no)
DE (2) DE4423131A1 (no)
DK (1) DK0769020T3 (no)
ES (1) ES2145280T3 (no)
GR (1) GR3033498T3 (no)
HU (1) HU221416B1 (no)
NO (1) NO965621L (no)
SK (1) SK284391B6 (no)
TW (1) TW458984B (no)
WO (1) WO1996001274A1 (no)
ZA (1) ZA955443B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
WO1999025732A2 (en) * 1997-11-13 1999-05-27 Europäisches Laboratorium für Molekularbiologie (EMBL) Design of coiled-coil dimer derived antagonists of 4-helix bundle cytokine specific receptors
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
IL161121A0 (en) 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
CA2513483C (en) * 2003-01-17 2011-11-29 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
UA94021C2 (ru) * 2003-08-29 2011-04-11 Байер Фармасьютикелз Корпорейшн Модифицированные антагонисты (мутеины) рецептора il-4
US7785580B2 (en) * 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
RU2389796C2 (ru) * 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
KR20080009111A (ko) * 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
MX2007012548A (es) * 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
AU2007204879A1 (en) * 2006-01-11 2007-07-19 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
AU2008274938A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
JP2009217498A (ja) * 2008-03-10 2009-09-24 Sato Knowledge & Intellectual Property Institute 印字試験システム
US8182626B2 (en) 2008-10-30 2012-05-22 Continental Ag Tire composition with improved vulcanizing agent
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
IN2015KN00329A (no) * 2012-08-09 2015-07-10 Univ Leland Stanford Junior
EP2813242A1 (en) * 2013-06-13 2014-12-17 PLS-Design GmbH Low molecular weight immune-modulators as adjuvants for specific immunotherapy
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12702710B2 (en) 2020-10-12 2026-08-11 Medicenna Therapeutics Inc. Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) * 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
DE3169595D1 (en) * 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) * 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3336583A1 (de) * 1983-09-26 1985-04-25 Udo Dr. 8400 Regensburg Ehrenfeld Erzeugnis zur diagnose und therapie von malignen tumoren
EP0143949B1 (en) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) * 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins
JPH02501827A (ja) * 1986-12-19 1990-06-21 イミュネックス・コーポレーション ヒト・インターロイキン‐４　ミューテイン
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538884A (en) * 1991-05-02 1996-07-23 Novo Nordisk A/S Rhamnogalacturonase, corresponding DNA sequence, rhamnogalacturonase containing enzyme preparation and use of the enzyme preparation
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
DK0769020T3 (da) 2000-07-31
WO1996001274A1 (de) 1996-01-18
JP2011102302A (ja) 2011-05-26
EP0769020B1 (de) 2000-03-01
ATE190068T1 (de) 2000-03-15
CZ292703B6 (cs) 2003-11-12
ZA955443B (en) 1996-02-13
DE59507920D1 (de) 2000-04-06
US6130318A (en) 2000-10-10
HU9603563D0 (en) 1997-02-28
TW458984B (en) 2001-10-11
ES2145280T3 (es) 2000-07-01
SK169296A3 (en) 1997-08-06
HUT77577A (hu) 1998-06-29
DE4423131A1 (de) 1996-01-04
SK284391B6 (sk) 2005-03-04
AU2885295A (en) 1996-01-25
JPH10502360A (ja) 1998-03-03
NO965621D0 (no) 1996-12-30
CA2193993C (en) 2008-11-18
AU705745B2 (en) 1999-06-03
KR100393508B1 (ko) 2003-10-23
CA2193993A1 (en) 1996-01-18
CZ384896A3 (en) 1997-06-11
HU221416B1 (en) 2002-09-28
GR3033498T3 (en) 2000-09-29
JP2007051161A (ja) 2007-03-01
EP0769020A1 (de) 1997-04-23

Similar Documents

Publication Publication Date Title
NO965621D0 (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
ATE182623T1 (de) Humanes serum albumin, herstellung und verwendung
ATE179330T1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
DK0764209T3 (da) Albuminekspression i gær
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
NO941681D0 (no) Humane IL-4 mutant proteiner
ATE170192T1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DK0609280T3 (da) Humane IL-3 varianter
ZA9510295B (en) Novel dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
ATE93388T1 (de) Paracetamol enthaltende arzneizubereitung.
KR950702207A (ko) Tlp 복합체에 대한 항원성 부위와 이의 항체(antigenic regions of tumour-liberated particles (tlp) complexes and antibodies against them)
DE59609483D1 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
DE69323191D1 (de) Wasserlösliche retinoide
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
FR2559157B1 (fr) Nouvel hexapeptide, son procede d'obtention et les compositions pharmaceutiques qui le contiennent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application